arrow_back Back Filing freshness 10-Q FY 2026 SEC EDGAR

HAEMONETICS CORP

HAE
$106.92 ▼ -1.66 (-1.53%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
19 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
64
Health
Fair
Bearish
auto_awesome

Analytical Summary

HAEMONETICS CORP faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $5.0B
Dividend Yield
Revenue Growth -2.0%
Op. Margin 11.7%
ROIC 5.9%
FCF / Share $5.52
Trailing P/E 51.9x
Price / Book 6.1x
FCF Yield 5.2%
Debt / Equity 1.56
info Valuation on last close. End-of-day price, Sep 23, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.33B
↓ -2.0%
Net Income Profit after all expenses
$97.31M
↓ -42.0%
Operating Margin Operating profit as % of sales
11.7%
↓ -27.9% 70th
FCF / Share Free cash flow per share
$5.52
↑ +95.0%
Long-Term Debt Long-term obligations
$1.24B
↓ -0.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
69
Returns
65
Financial Health
45
Cash Quality
89

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 71 quarters